Valuation dashboard for Quince Therapeutics, Inc. (QNCX) with P/E N/A, P/B 1.43, EV/EBITDA 1.48 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $27.17, QNCX has negative trailing earnings (P/E not meaningful) and an ROE of -413.28%. Market capitalisation stands at $8M.
Balance sheet quality for QNCX: current ratio of 0.5. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 1.43 |
| EV / EBITDA | 1.48 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-45.31 |
| vs Current Price | -266.8% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| QNCX | Quince Therapeutics, Inc. | $8M | 1.43 | -413.3% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $27.17 |
| Market Cap | $8M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -413.28% |
| Return on Invested Capital | -104.64% |
| Return on Assets | -74.58% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ADVM · ALXO · ATYR · CAMP · CNTB · DTIL · GUTS
Explore sector: Healthcare · Biotechnology
More sections of QNCX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks